Welcome to our dedicated page for Seer SEC filings (Ticker: SEER), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Seer, Inc.'s SEC filings document material events, operating results, securityholder rights and governance matters for a Nasdaq-listed life sciences company focused on research-use proteomics. Recent 8-K reports cover results of operations and financial condition, material definitive agreements, modifications to securityholder rights, other events and related exhibits.
The filings disclose Seer's Class A common stock, Preferred Stock Purchase Rights, Tax Benefit Preservation Plan for net operating loss and other tax attributes, amendments to that plan, and the completed conversion of Class B common stock into Class A common stock. They also record board and shareholder matters, leadership appointments, and intellectual-property updates related to the Proteograph Product Suite and particle-based protein enrichment.
Seer, Inc. has filed a preliminary proxy statement for its 2026 Annual Meeting where seven directors will be elected and four proposals will be voted, including ratification of Deloitte & Touche LLP and a Tax Benefit Preservation Plan through February 25, 2029. The filing details an active proxy contest: the Radoff-JEC Group disclosed holdings of approximately 6.5%–7.6% and intends to nominate three director candidates in opposition to three of Seer’s nominees. The board urges shareholders to use the BLUE proxy card and vote FOR Seer’s slate and all proposals. The filing also describes recent repurchase program activity and related engagement with the Radoff-JEC Group.
Seer, Inc. reports amended beneficial ownership for Omid Farokhzad. The amendment states Mr. Farokhzad beneficially owns 6,918,732 shares of Class A common stock, representing 12.0% of the class. The calculation cites 54,981,551 shares outstanding as of May 8, 2026 and 2,515,008 options exercisable within 60 days of March 31, 2026. The total includes 2,117,138 shares held of record by a trust for which his spouse is trustee; the Reporting Person disclaims beneficial ownership of those trust-held shares.
Seer, Inc. reported Q1 2026 revenue of $2.8M, down from $4.2M a year earlier as both product and service sales declined. Gross profit fell to $1.0M from $2.1M.
The company posted a net loss of $16.8M for the quarter, an improvement from a $19.9M loss in Q1 2025, helped by lower research and development and selling, general and administrative expenses, including reduced stock-based compensation.
Seer ended March 31, 2026 with $219.5M in cash, cash equivalents and investments and an accumulated deficit of $482.8M. Operating cash outflow was $15.4M. The company repurchased about 1.46M Class A shares for $2.6M and believes its current liquidity can fund operations for at least twelve months.
Seer, Inc. reported first quarter 2026 revenue of $2.8 million, down 34% from $4.2 million a year earlier, as academic funding remained weak and competition increased. Product revenue was $2.1 million, service revenue $596 thousand, and other revenue $87 thousand.
Gross profit was $982 thousand with a 35% gross margin. Operating expenses fell 20% to $18.2 million, helping narrow the net loss to $16.8 million from $19.9 million. Free cash flow was approximately negative $15.7 million. Seer ended the quarter with about $220 million in cash, cash equivalents, and investments and repurchased approximately 1.5 million Class A shares.
The company reaffirmed its full year 2026 revenue outlook of $16 million to $18 million, implying about 3% growth at the midpoint over 2025. Management highlighted new collaborations, increased third-party publications supporting its platform, leadership additions, and a favorable patent office decision as building blocks for long-term growth.
Seer, Inc. disclosed that Chief Commercial Officer Anthony R. Bazarko received an equity compensation grant. He was awarded 75,000 shares of Class A Common Stock in the form of restricted stock units that vest in four equal annual installments beginning on May 15, 2027. He also received an option on 225,000 shares of Class A Common Stock with an exercise price of $1.87 per share, expiring on May 8, 2036. One-fourth of the option shares vest on May 4, 2027, with the remainder vesting monthly thereafter. These awards are reported as grants, not open-market purchases or sales.
Seer, Inc. filed an initial insider ownership report for Chief Commercial Officer Anthony R. Bazarko. This Form 3 does not list any specific share transactions or derivative positions and serves as a baseline disclosure of his status as an officer subject to insider reporting rules.
Seer, Inc. has appointed Anthony Bazarko as its new Chief Commercial Officer. He brings more than two decades of commercial leadership experience across life sciences, diagnostics, and biotechnology, including prior roles as President and CEO of Biologos and Chief Commercial Officer at Specific Diagnostics.
At Seer, Bazarko will lead Sales, Marketing and Customer Experience to strengthen commercial execution and support the next phase of growth for the Proteograph® Product Suite. Seer highlights his track record in driving revenue growth, building high-performing teams, and leading global go-to-market strategies.
Invus Public Equities and related entities filed an Amendment No. 4 to Schedule 13G/A reporting beneficial ownership of 2,458,673 shares of Seer, Inc. Class A common stock as of March 31, 2026. The filing states this equals 4.4% of the class based on 56,420,772 shares outstanding as of February 23, 2026. The cover lists affiliated reporting persons — Invus Public Equities, Invus PE Advisors, Invus Global Management, Siren, L.L.C., and Raymond Debbane — and describes control relationships that could cause each to be deemed the beneficial owner. The filing certifies the shares were not acquired to change or influence control.
Seer, Inc. filed Amendment No. 1 to its annual report for the year ended December 31, 2025 to add the Part III sections on directors, governance and executive compensation. The filing details a seven‑member board, of which five are Nasdaq‑defined independent directors, and describes committee structures and meeting activity.
Non‑employee director pay combines cash retainers and equity, with standard annual cash fees of $42,500 for board service and additional amounts for committee and lead roles. The amendment also outlines 2025 compensation and outstanding equity awards for the CEO and President/CFO, along with severance and change‑in‑control protections and equity plan features.